申请人:Hatley Richard Jonathan Daniel
公开号:US20100168122A1
公开(公告)日:2010-07-01
The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial
本发明涉及公式(I)的化合物,它们是黄嘌呤衍生物,制备这些衍生物的过程,含有这些化合物的药物配方以及在治疗中使用这些化合物,例如,在疾病治疗中,HM74A受体的欠活化对疾病有贡献或激活受体将有益的情况下。